NxStage (NXTM) Receives Average Recommendation of “Hold” from Brokerages

Shares of NxStage (NASDAQ:NXTM) have been given an average recommendation of “Hold” by the eleven brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and nine have issued a hold rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $30.00.

A number of research analysts have issued reports on the company. ValuEngine upgraded NxStage from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research upgraded NxStage from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Finally, BidaskClub upgraded NxStage from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th.

How to Become a New Pot Stock Millionaire

NxStage stock traded down $0.44 during midday trading on Thursday, reaching $25.42. The company’s stock had a trading volume of 272,289 shares, compared to its average volume of 570,961. NxStage has a 52 week low of $20.45 and a 52 week high of $30.80. The stock has a market cap of $1,716.38, a PE ratio of -363.14 and a beta of -0.01.

In other news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $24.48, for a total transaction of $85,680.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of NxStage by 2.8% in the fourth quarter. BlackRock Inc. now owns 4,397,090 shares of the medical device company’s stock worth $106,542,000 after acquiring an additional 118,014 shares during the period. Alpine Associates Management Inc. lifted its stake in shares of NxStage by 1.1% in the fourth quarter. Alpine Associates Management Inc. now owns 4,035,237 shares of the medical device company’s stock worth $97,774,000 after acquiring an additional 43,779 shares during the period. Pennant Capital Management LLC lifted its stake in shares of NxStage by 8.3% in the fourth quarter. Pennant Capital Management LLC now owns 1,756,354 shares of the medical device company’s stock worth $42,556,000 after acquiring an additional 134,288 shares during the period. State of Wisconsin Investment Board lifted its stake in shares of NxStage by 117.6% in the fourth quarter. State of Wisconsin Investment Board now owns 1,056,447 shares of the medical device company’s stock worth $25,598,000 after acquiring an additional 570,847 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of NxStage by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 750,244 shares of the medical device company’s stock worth $18,177,000 after acquiring an additional 43,169 shares during the period. Institutional investors own 84.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “NxStage (NXTM) Receives Average Recommendation of “Hold” from Brokerages” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/19/nxstage-nxtm-receives-average-recommendation-of-hold-from-brokerages.html.

About NxStage

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Analyst Recommendations for NxStage (NASDAQ:NXTM)

Receive News & Ratings for NxStage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply